However, we did not adopt stopping rules concerning negative or positive response prediction biomarkers by the two reasons as follows: (a) Peg-IFN therapy is reported that the therapy might have potential to suppress HCC occurrence in HBV-infected patients [39]; (b) Recently, two randomized controlled trials (RCTs) using Peg-IFN with nucleos(t)ide analogues to achieve HBsAg seroclearance were reported [17,18]. This evidence concerns the gene IFNA1 and hepatocellular carcinoma.